Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Eyenovia Inc (EYEN) Misses Q4 EPS by 17c
March 27, 2019 6:31 AM EDTEyenovia Inc (NASDAQ: EYEN) reported Q4 EPS of ($0.60), $0.17 worse than the analyst estimate of ($0.43).
Reported positive results in the MicroStat Phase III MIST-1 and MIST-2 registration studies for mydriasis;U.S. Food and Drug Administration (FDA) accepted investigational new drug (IND) application to initiate MicroPine Phase III CHAPERONE registration study to reduce the progression of myopia in children;Expanded and streamlined the MicroProst Phase III program to include chronic angle closure glaucoma (CACG), as well as open angle glaucoma (OAG) and ocular hypertension (OHT) patients in a single registration... More